BioNTech

AACR: Merck unveils PD-1xVEGF bispecific data in NSCLC

In what Merck describes as “early signs of promising anti-tumor activity,” the PD-1xVEGF bispecific, coded MK-2010, induced an unconfirmed ORR of 55%.

Angus Liu Apr 17, 2026 3:00pm

BioNTech, SynOx plot paths to FDA as tumor trials hit goals

Apr 13, 2026 5:10am

BioNTech founders to pioneer new company—Chutes & Ladders

Mar 13, 2026 8:30am

BioNTech's CEO, CMO will depart to set up next-gen mRNA company

Mar 10, 2026 6:30am

weigh scale goliath outweigh balance bigger smaller even

BioNTech’s B7-H3 ADC hits ph. 3 at half the size of Merck’s

Feb 27, 2026 10:31pm

A tied stack of one hundred dollar bills lying on a euro bills background

Biotech money moves: 3 new venture funds raise nearly $1B

Jan 9, 2026 1:20pm